NON-INVASIVE INFANT MENINGITIS SCREENING AND MONITORING

Neosonics is a first-in-class medical device to non-invasively screen and monitor infant meningitis. Neosonics uses high-resolution ultrasound, unique coupling materials and artificial intelligence to automatically count at the push of a button and in just a few seconds white blood cells (WBC) in the cerebrospinal fluid (CSF) directly below the infant fontanel, a well-established marker of infant meningitis screening and treatment monitoring.

Meningitis detection is challenging due to the unspecific signs associated to the infection, especially among youngest infants and newborns. Quick, easy and cost-effective, Neosonics will allow to confirm accurate suspicion of meningitis and to provide accurate diagnosis and treatment at a lower cost.

This is an investigational device. It is not for sale. The claims made on this website have not been evaluated by the FDA or the CE Mark authorities.

WHAT MAKES
NEOSONICS A
UNIQUE DEVICE ?

WHAT MAKES NEOSONICS A UNIQUE DEVICE ?

  • QUICK: fully automatic cell count in seconds
  • EASY TO USE: 1 non-expert user (nurse or paediatrician)
  • NON-INVASIVE: novel ultrasound technology
  • TREATMENT MONITORING: allows frequent measurements
  • COST-EFFECTIVE: up to 47% of costs savings

QUICK & EASY TO USE IN 3 STEPS

PLACE

Place Neosonics on the infant’s fontanel. Automatic position check guarantees an optimal use.

PUSH

Push the button to acquire WBC count in CSF within seconds.

DETECT

Detect abnormal WBC count in CSF to immediately trigger medication or to follow-up patient’s response to treatment.

PLACE

Place Neosonics on the infant’s fontanel, the head area where bones are not yet closed

PUSH

Push the button to get the
cerebrospinal fluid (CSF)
white blood cell (WBC)

DETECT

Detect abnormal CSF WBC count to immediately trigger medication or to follow-up patient’s response to treatment

FIRST-IN-CLASS MEDICAL DEVICE

ACCOMPLISHMENTS

Automatic CSF segmentation
(60 patients)
Granted patent

SENSITIVITY TO ANY CELL CONCENTRATION

Clinical Proof of Concept
100% sensitivity & specificity
Detection limit accuracy
3 cells/µL (20 patients)

FEASIBILITY ON PATIENTS

Efficacy study (176 patients)
*CE Mark pending

100% ACCEPTANCE MARKET STUDY

Cost-effective utility study: Post-commercialisation study
(expected date Q4 2023)

WILLINGNESS TO PAY FROM FUTURE CUSTOMERS

THE NEW STANDARD FOR SCREENING AND TREATMENT MONITORING

Non-invasive CSF white blood cell count to screen and monitor for infant meningitis with Neosonics.

Let's keep in touch!

Want to know about our project updates and latest news?

Non-invasive screening and monitoring of infections in serous body fluids. Neosonics™ and Newborn Solutions™ are protected trademarks of Newborn Solutions. We partner with El Corriol to power our website and web design.

WARNING:

Content featured on this site is exclusively addressed to healthcare and medical technology specialists. Following products are under development and/or validation processes and they are not ready for commercialization.

ARE YOU A HEALTHCARE PROFESSIONAL?

NO
YES